Rain Oncology Q3 EPS $(0.19) Beats $(0.27) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rain Oncology (NASDAQ:RAIN) reported Q3 losses of $(0.19) per share, beating the analyst consensus estimate of $(0.27) by 29.63%. This represents a 72.06% increase over losses of $(0.68) per share from the same period last year.
November 09, 2023 | 9:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rain Oncology's Q3 losses were less than expected, which could be seen as a positive sign by investors.
Rain Oncology reported lower than expected losses for Q3, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100